We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Anti-Rejection Therapy in Renal Transplantation: Use of the Monoclonal Antibody OKT3.
- Authors
Nicholson, M. L.; Donnelly, P. K.; Veitch, P. S.; Bell, P. R. F.
- Abstract
The success of anti-rejection therapy was evaluated in 65 cadaveric renal allografts immunosuppressed with cyclosporin. All first rejection episodes were treated with 0.5 g methylprednisolone given daily for 3 days. Second rejection episodes were treated with either a further identical 3-day course of methylprednisolone or a 10–14-day course of the monoclonal antibody OKT3. The peak creatinine during second rejection episodes was higher in patients treated with OKT3 (481±54 μmol/1; mean±SEM) than in those treated with methylprednisolone (320±59 μmol/1) (P = 0.036), suggesting more severe rejection in the OKT3 group. Despite this the rejection reversal rate was higher in the OKT3-treated group (100%) when compared to the high-dose methylprednisolone group (64%) (P<0.05) and the creatinine at 6 months was less in the OKT3 group (162±17 μmol/1) than in the methylprednisolone group (230±22 μmol/1). These data suggest that OKT3 is a very effective treatment for second rejection episodes following renal transplantation and yields improved renal functions in comparison with high-dose steroids.
- Publication
Nephrology Dialysis Transplantation, 1991, Vol 6, Issue 4, p275
- ISSN
0931-0509
- Publication type
Article